Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.

Antimicrobial agents and chemotherapy - 1 Nov 2015

Liu Rong, Curry Stephanie, McMonagle Patricia, Yeh Wendy W, Ludmerer Steven W, Jumes Patricia A, Marshall William L, Kong Stephanie, Ingravallo Paul, Black Stuart, Pak Irene, DiNubile Mark J, Howe Anita Y M

Abstract excerpt

Elbasvir is an investigational NS5A inhibitor with in vitro activity against multiple HCV genotypes. Antiviral activity of elbasvir was measured in replicons derived from wild-type or resistant variants of genotypes 1a, 1b, and 3. The barrier to resistance was assessed by the number of resistant colonies selected by exposure to various elbasvir concentrations. In a phase 1b dose-escalating study, virologic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Benzofurans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C virus research

Share to Imidazoles

Share to Replicon

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 26303801
DOI: 10.1128/AAC.01390-15
PMCID: PMC4604396

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.PMID 26303801Read ↗

Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus.Semantic proximity Read ↗

Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance.Semantic proximity Read ↗

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.Semantic proximity Read ↗

Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.Semantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Semantic proximity Read ↗

Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.Semantic proximity Read ↗

Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitorsSemantic proximity Read ↗

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.Semantic proximity Read ↗

Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.Semantic proximity Read ↗

Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor.Semantic proximity Read ↗

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.Semantic proximity Read ↗

<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5ASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.